Clinical trials: Influenza in Humans
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in children compared to two other influenza vaccines.
- Trial name
- NCT01198756
- Testing
- Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 3,109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Virus Infection Transmission in Humans
Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
The recent swine origin influenza pandemic (2009), new emergence of swine origin H3N2v, and delayed availability of vaccine for these agents highlight the need to test and optimize public health intervention strategies to reduce…
- Trial name
- EMIT (NCT01769430)
- Testing
- Observational Study of influenza aerosol shedding -- No Intervention
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- University of Maryland, College Park
Human Influenza
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.
- Trial name
- NCT02387294
- Testing
- Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml), Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
- Trial name
- NCT01776541
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis
Immunologic Tests
A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
The purpose of this exploratory, retrospective laboratory study is to assess the humoral immune response to H1 hemagglutinin stalk domain and other influenza A virus protein epitopes following administration, in adults and…
- Trial name
- NCT02415842
- Testing
- Serum samples
- Where
- United States
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults
The study is aim to evaluate the immunogenicity and safety with two groups of participants who will received a seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed…
- Trial name
- NCT03390166
- Testing
- GPO Tri Fluvac vaccine, Licensed influenza vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 945 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Influenza, Influenza-like Illness
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the…
- Conditions
- Influenza, Influenza-like Illness, Influenza Vaccines
- Trial name
- PAIVED (NCT03734237)
- Testing
- Egg based influenza vaccines, Recombinant influenza vaccines, Cell-culture based influenza vaccines
- Where
- 9 sites in United States
- Volunteers
- 15,448 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
The study will evaluate the safety and immunogenicity of the 2014-2015 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02222870
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase 3 Trial of Serbian Seasonal Influenza Vaccine
A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by InstituteTorlak.
- Trial name
- Torlak-300 (NCT02935192)
- Testing
- Vaccine
- Where
- 6 sites in Serbia
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Institute of Virology, Vaccines and Sera, Torlak
Influenza
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
A study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with Fluarix™
- Trial name
- NCT00377611
- Testing
- Fluarix™
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 3,054 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata)…
- Trial name
- NCT01712984
- Testing
- Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
- Where
- 38 sites in United States
- Volunteers
- 3,360 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Haemophilus Influenza
A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children.
- Trial name
- NCT02692859
- Testing
- Hib conjugate vaccine
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly…
- Trial name
- NCT02369341
- Testing
- Fluarix Tetra
- Where
- 2 sites in Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Influenza
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
The study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.
- Trial name
- NCT00372255
- Testing
- Influsplit SSW® 2005/2006
- Where
- 18 sites in Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine. Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the same vaccine for the third time.
- Trial name
- NCT00992784
- Testing
- GSK investigational vaccine 2186877A, FluarixTM
- Where
- 24 sites in Germany, Netherlands and 1 more
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.
- Trial name
- NCT05868382
- Testing
- mRNA-1010, mRNA-1010.4, mRNA-1010.6
- Where
- 10 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer